Intradermal hepatitis B vaccination in an abbreviated schedule

Neal A Halsey, Earl J. Reppert, Harold S. Margolis, Donald P. Francis, Howard A. Fields

Research output: Contribution to journalArticle

Abstract

Two low-dose intradermal regimens for hepatitis B vaccination were compared with the standard 1 ml dose administered intramuscularly to healthy, 22-42 year old individuals. All regimens were administered in an abbreviated time schedule. Nineteen individuals (ID-1 group) received three 0.1 ml (2 μg) doses intradermally at times 0, 1 month and 4 months. Twenty-four individuals (ID-2 group) received two injections of 0.2 ml (4 μg) each intradermally at time 0 and one 0.1 ml (2 μg) injection 4 months later. Twenty individuals (IM group) received the recommended three 1.0 ml (20 μg) doses intramuscularly at times 0, 1 month, and 4 months. No significant adverse reactions were attributable to the intradermal administration of vaccine although the majority of vaccinees developed small areas of induration and hyperpigmentation at the injection site that persisted for several months. One month following the last injection, all vaccinees had developed anti-HBsAg antibodies. One hundred percent of ID-1 and IM vaccinees and 95% of ID-2 vaccinees had protective levels of antibody (≥10 mIU ml-1). The geometric mean titre (GMT) for the IM group (2692 mIU ml-1) was somewhat higher than for the ID-1 (1230 mIU ml-I) and the ID-2 (851 mIU ml-1) groups, but the differences were not statistically significant. Since anti-HBs antibodies are thought to confer protection against hepatitis B, these results suggest that a shortened regimen of intradermal vaccine may be effective in healthy adults. However, no efficacy study has yet been done with intradermal hepatitis B vaccine.

Original languageEnglish (US)
Pages (from-to)228-232
Number of pages5
JournalVaccine
Volume4
Issue number4
DOIs
StatePublished - 1986
Externally publishedYes

Fingerprint

hepatitis B
Hepatitis B
Appointments and Schedules
Vaccination
vaccination
vaccines
injection
Injections
antibodies
dosage
Anti-Idiotypic Antibodies
Vaccines
injection site
administered dose
Hepatitis B Vaccines
Hyperpigmentation
Hepatitis B Surface Antigens
Antibodies
N-Tyr-delta sleep-inducing peptide

Keywords

  • Hepatitis B
  • intradermal vaccination
  • trial

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Halsey, N. A., Reppert, E. J., Margolis, H. S., Francis, D. P., & Fields, H. A. (1986). Intradermal hepatitis B vaccination in an abbreviated schedule. Vaccine, 4(4), 228-232. https://doi.org/10.1016/0264-410X(86)90134-9

Intradermal hepatitis B vaccination in an abbreviated schedule. / Halsey, Neal A; Reppert, Earl J.; Margolis, Harold S.; Francis, Donald P.; Fields, Howard A.

In: Vaccine, Vol. 4, No. 4, 1986, p. 228-232.

Research output: Contribution to journalArticle

Halsey, NA, Reppert, EJ, Margolis, HS, Francis, DP & Fields, HA 1986, 'Intradermal hepatitis B vaccination in an abbreviated schedule', Vaccine, vol. 4, no. 4, pp. 228-232. https://doi.org/10.1016/0264-410X(86)90134-9
Halsey, Neal A ; Reppert, Earl J. ; Margolis, Harold S. ; Francis, Donald P. ; Fields, Howard A. / Intradermal hepatitis B vaccination in an abbreviated schedule. In: Vaccine. 1986 ; Vol. 4, No. 4. pp. 228-232.
@article{60b6bd368cd548c59f9b3a31624b6b22,
title = "Intradermal hepatitis B vaccination in an abbreviated schedule",
abstract = "Two low-dose intradermal regimens for hepatitis B vaccination were compared with the standard 1 ml dose administered intramuscularly to healthy, 22-42 year old individuals. All regimens were administered in an abbreviated time schedule. Nineteen individuals (ID-1 group) received three 0.1 ml (2 μg) doses intradermally at times 0, 1 month and 4 months. Twenty-four individuals (ID-2 group) received two injections of 0.2 ml (4 μg) each intradermally at time 0 and one 0.1 ml (2 μg) injection 4 months later. Twenty individuals (IM group) received the recommended three 1.0 ml (20 μg) doses intramuscularly at times 0, 1 month, and 4 months. No significant adverse reactions were attributable to the intradermal administration of vaccine although the majority of vaccinees developed small areas of induration and hyperpigmentation at the injection site that persisted for several months. One month following the last injection, all vaccinees had developed anti-HBsAg antibodies. One hundred percent of ID-1 and IM vaccinees and 95{\%} of ID-2 vaccinees had protective levels of antibody (≥10 mIU ml-1). The geometric mean titre (GMT) for the IM group (2692 mIU ml-1) was somewhat higher than for the ID-1 (1230 mIU ml-I) and the ID-2 (851 mIU ml-1) groups, but the differences were not statistically significant. Since anti-HBs antibodies are thought to confer protection against hepatitis B, these results suggest that a shortened regimen of intradermal vaccine may be effective in healthy adults. However, no efficacy study has yet been done with intradermal hepatitis B vaccine.",
keywords = "Hepatitis B, intradermal vaccination, trial",
author = "Halsey, {Neal A} and Reppert, {Earl J.} and Margolis, {Harold S.} and Francis, {Donald P.} and Fields, {Howard A.}",
year = "1986",
doi = "10.1016/0264-410X(86)90134-9",
language = "English (US)",
volume = "4",
pages = "228--232",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Intradermal hepatitis B vaccination in an abbreviated schedule

AU - Halsey, Neal A

AU - Reppert, Earl J.

AU - Margolis, Harold S.

AU - Francis, Donald P.

AU - Fields, Howard A.

PY - 1986

Y1 - 1986

N2 - Two low-dose intradermal regimens for hepatitis B vaccination were compared with the standard 1 ml dose administered intramuscularly to healthy, 22-42 year old individuals. All regimens were administered in an abbreviated time schedule. Nineteen individuals (ID-1 group) received three 0.1 ml (2 μg) doses intradermally at times 0, 1 month and 4 months. Twenty-four individuals (ID-2 group) received two injections of 0.2 ml (4 μg) each intradermally at time 0 and one 0.1 ml (2 μg) injection 4 months later. Twenty individuals (IM group) received the recommended three 1.0 ml (20 μg) doses intramuscularly at times 0, 1 month, and 4 months. No significant adverse reactions were attributable to the intradermal administration of vaccine although the majority of vaccinees developed small areas of induration and hyperpigmentation at the injection site that persisted for several months. One month following the last injection, all vaccinees had developed anti-HBsAg antibodies. One hundred percent of ID-1 and IM vaccinees and 95% of ID-2 vaccinees had protective levels of antibody (≥10 mIU ml-1). The geometric mean titre (GMT) for the IM group (2692 mIU ml-1) was somewhat higher than for the ID-1 (1230 mIU ml-I) and the ID-2 (851 mIU ml-1) groups, but the differences were not statistically significant. Since anti-HBs antibodies are thought to confer protection against hepatitis B, these results suggest that a shortened regimen of intradermal vaccine may be effective in healthy adults. However, no efficacy study has yet been done with intradermal hepatitis B vaccine.

AB - Two low-dose intradermal regimens for hepatitis B vaccination were compared with the standard 1 ml dose administered intramuscularly to healthy, 22-42 year old individuals. All regimens were administered in an abbreviated time schedule. Nineteen individuals (ID-1 group) received three 0.1 ml (2 μg) doses intradermally at times 0, 1 month and 4 months. Twenty-four individuals (ID-2 group) received two injections of 0.2 ml (4 μg) each intradermally at time 0 and one 0.1 ml (2 μg) injection 4 months later. Twenty individuals (IM group) received the recommended three 1.0 ml (20 μg) doses intramuscularly at times 0, 1 month, and 4 months. No significant adverse reactions were attributable to the intradermal administration of vaccine although the majority of vaccinees developed small areas of induration and hyperpigmentation at the injection site that persisted for several months. One month following the last injection, all vaccinees had developed anti-HBsAg antibodies. One hundred percent of ID-1 and IM vaccinees and 95% of ID-2 vaccinees had protective levels of antibody (≥10 mIU ml-1). The geometric mean titre (GMT) for the IM group (2692 mIU ml-1) was somewhat higher than for the ID-1 (1230 mIU ml-I) and the ID-2 (851 mIU ml-1) groups, but the differences were not statistically significant. Since anti-HBs antibodies are thought to confer protection against hepatitis B, these results suggest that a shortened regimen of intradermal vaccine may be effective in healthy adults. However, no efficacy study has yet been done with intradermal hepatitis B vaccine.

KW - Hepatitis B

KW - intradermal vaccination

KW - trial

UR - http://www.scopus.com/inward/record.url?scp=0022858708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022858708&partnerID=8YFLogxK

U2 - 10.1016/0264-410X(86)90134-9

DO - 10.1016/0264-410X(86)90134-9

M3 - Article

VL - 4

SP - 228

EP - 232

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 4

ER -